Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;485(5):761-775.
doi: 10.1007/s00428-024-03933-2. Epub 2024 Oct 2.

Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology

Affiliations
Review

Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology

Marius Ilié et al. Virchows Arch. 2024 Nov.

Abstract

Despite advancements in precision medicine, many cancer patients globally, particularly those in resource-constrained environments, face significant challenges in accessing high-quality molecular testing and targeted therapies. The considerable heterogeneity in molecular testing highlights the urgent need to harmonize practices across Europe and beyond, establishing a more standardized and consistent approach in MP laboratories. Professionals, especially molecular pathologists, must move beyond traditional education to cope with this heterogeneity. This perspective addresses critical issues in molecular pathology (MP), such as limited access to high-quality molecular testing, leading to disparities in cancer treatment, and the consequences of inconsistent practices. Recognizing the necessity for a standardized framework for education to address these issues, educational programs play a pivotal role in updating professionals' skills to achieve standardization in MP. European experts from the Steering Committee, the Pathology Section of the European Union of Medical Specialists, and the European Society of Pathology have proposed creating a comprehensive Master's degree program called the "European Masters in Molecular Pathology" (EMMP). This program emerges as a strategic response to the demand for a specialized and standardized framework for education in MP, catering to professionals who concurrently work and study. The program's design aligns with evidence-based education methods, ensuring effective learning and engagement while integrating computational pathology to analyze complex molecular data, enhance diagnostic accuracy, and improve treatment outcomes. EMMP's structured curriculum, strategic partnerships, and regular updates underscore its significance in standardizing MP practices. Exploring future developments, this perspective delves into technology integration and interdisciplinary collaboration, anticipating ongoing advances and harmonization. Challenges and future directions in MP education are discussed, emphasizing the necessity for dynamic curriculum updates, seamless technology integration, and interdisciplinary cooperation. This perspective underscores EMMP's pivotal role in preparing pathologists for this dynamic field, advocating continuous advancements in education and training to uphold excellence in MP practices and maintain the highest patient care standards.

Keywords: Education; Europe; Masters; Molecular pathology; Standardization.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing interests M. Ilié: honoraria from AstraZeneca and MSD, and research funding from Amgen. A. Diepstra: research funding from Takeda. C. Eloy: advisory role for MSD, Leica, Diapath, Biocartis, Sakura, Mindpeak. F. Fend: research funding from Stemline; speaker honoraria from Stemline, EUSA Pharma. G. Hoefler: honoraria from AstraZeneca, Elsevier, MSD, Novartis, BioProducts. M. Hummel: honoraria for Novartis, AstraZeneca. E. Schuuring reports lectures for Bio-Rad, Seracare, Roche, Biocartis, Illumina, Lilly, Janssen Cilag (Johnson&Johnson), AstraZeneca, and Agena Bioscience; he is consultant in advisory boards for MSD/Merck, GSK, AstraZeneca, Astellas Pharma, Sysmex, Roche, Novartis, Bayer, BMS, Lilly, Amgen, Illumina, Agena Bioscience, Janssen Cilag (Johnson&Johnson), Sinnovisionlab, Diaceutics, CC Diagnostics; and received research grants from Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bio-science, BMS, Bio-Rad, Roche, Boehringer Ingelheim, CC Diagnostics, SNN/EFRO, and Abbott (all paid to UMCG account); and travel reimbursements from Bio-Rad, Abbott, Illumina, Agena Bioscience, Roche, IQNPath, and BioRAD. W. Timens: honororia to UMCG from Bristol-Myers Squibb, Merck Sharp Dohme. C. Benedikt Westphalen: has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, Janssen, Ipsen, MSD, Merck, Roche, Servier, SIRTeX, Taiho; served on advisory boards for Bayer, BMS, Celgene, Incyte, Janssen, Lily, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, Roche, has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, Taiho and research grants (institutional) from Roche; serves as faculty for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), and Arbeitsgemeinschaft internistische Onkologie (AIO), is a member of the EU Commission expert group: mission board for cancer; is a member of the forum #Zukunftsstrategie of the German government. P. Hofman: advisory role for: Sanofi, Amgen, Roche, Abbvie, BMS, AstraZeneca, Pfizer, Janssen, Pierre Fabre, ThermoFisher Scientific, Qiagen, Diaceutics, Novartis, Biodena, Biocartis, Eli Lilly; honoraria from: Sanofi, Amgen, Roche, BMS, AstraZeneca, Abbvie, Qiagen, Pfizer, Janssen, Pierre Fabre, ThermoFisher Scientific, Biodena, Diaceutics, Biocartis, Daiichi-Sankyo, Eli Lilly, Bayer, Novartis, Bayer; grant/research funding from: Amgen, Thermo-Fisher Scientific, Biodena, Roche. The remaining authors declare no conflicts of interest.

References

    1. Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28:658–665 - DOI - PubMed
    1. Akhoundova D, Rubin MA (2022) Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell 40:920–938 - DOI - PubMed
    1. Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J et al (2022) Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer 176:70–77 - DOI - PubMed
    1. de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R et al (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health - Europe 38:100838 - DOI - PubMed
    1. Hofman P, Calabrese F, Kern I, Adam J, Alarcao A, Alborelli I et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8:101628 - DOI - PubMed - PMC

LinkOut - more resources